Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H6ClF2N3O |
| Molecular Weight | 269.635 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=C(F)C=C(C=C1)C(=O)NC2=CN=C(Cl)N=C2
InChI
InChIKey=IIBSHMFXVWTQSJ-UHFFFAOYSA-N
InChI=1S/C11H6ClF2N3O/c12-11-15-4-7(5-16-11)17-10(18)6-1-2-8(13)9(14)3-6/h1-5H,(H,17,18)
The novel compound ICA-069673 was developed by Icagen, Inc. in a screening program to identify subtype-selective KV7 channel activators. It was found, that this compound is a selective KV7.2/KV7.3 (KCNQ2/3) channel opener, which possesses 20-fold selectivity for KV7.2/KV7.3 over KV7.3/KV7.5, with no measurable activity over a panel of cardiac ion channels. ICA-06967 was orally active in animal models and was used for epilepsy.
Approval Year
Sample Use Guides
in rats: maximal electroshock (MES) and the PTZ anticonvulsant assays: MES ED50 = 1.5 mg/kg, PTZ ED50 = 2.2 mg/kg
Route of Administration:
Oral
It was measured the effects of ICA-069673 on global intracellular Ca2+ levels in detrusor smooth muscle (DSM) single cells. For the control, the average emitted intensity (F340/F380) prior to ICA-069673 application was 0.470 ± 0.006 (n = 11, N = 5). At 10 μM ICA-069673, there was a significant decrease in the F340/F380 ratio to 0.450 ± 0.006 (n = 11, N = 5; P < 0.001). To elucidate the mechanism by which ICA-069673 regulates global intracellular Ca2+ concentrations, it was studied the effects of ICA-069673 (10 µM) in the presence or absence of the L-type CaV channel blocker nifedipine (1 µM). In the presence of 1 µM nifedipine, ICA-069673 (10 µM) had no significant effect on global intracellular Ca2+ levels, with the average F340/F380 ratio being 0.470 ± 0.008 compared with the control value of 0.480 ± 0.005 (n = 11, N = 5; P > 0.05). These results demonstrate that in DSM cells, ICA-069673 decreases global intracellular Ca2+ concentrations by an indirect mechanism involving inhibition of Ca2+influx through L-type CaV channels, probably as a result of membrane hyperpolarization.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
582323-16-8
Created by
admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
|
PRIMARY | |||
|
10149311
Created by
admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
|
PRIMARY | |||
|
KvLQT2
Created by
admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
|
PRIMARY | ICA-069673: channel opener at KCNQ2/Q3, 20-fold selective over KCNQ3/Q5, no measurable activity against a panel of cardiac ion channels (hERG, Nav1.5, L type channels, and KCNQ1) and no activity on GABAA gated channels at 10 .MU.M. A range of related benzamides exhibited activity, of which compound number 40 is shown here. ML252: channel inhibitor, IC50 = 70nM. | ||
|
ICA-069673
Created by
admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
|
PRIMARY | ICA 069673 is a potassium channel opener with selective action for KCNQ2 and KCNQ3 (EC50=0.69 .MU.M). No measurable activity was displayed over a variety of cardiac ion channels. IC50: Voltage-gated potassium channel, KQT; KCNQ2(Kv7.2)/KCNQ3(Kv7.3): EC5050 = 0.69 undefinedM (human); HERG: IC50 >30 undefinedM (human); Na+ CP type V.ALPHA.: IC50 >30 undefinedM (human) - pK Values: pKa: 9.47 (Predicted) | ||
|
NCO5DC74G8
Created by
admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
